Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Losmapimod · FTX-1821

Small molecule · Inhibitor of p38 MAPK alpha/beta (MAPK14) · developed by Fulcrum Therapeutics

Phase 3 Most advanced trial (none active)
FULC Developer
3 Registered trials

What is Losmapimod?

Losmapimod is an orally bioavailable inhibitor of the alpha and beta isoforms of p38 mitogen-activated protein kinase. It suppresses p38 alpha/beta signaling, which reduces production of proinflammatory cytokines such as TNF-alpha, IL-1, IL-6 and IL-8. It is studied in COVID-19 and facioscapulohumeral muscular dystrophy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
FTX-1821
Drug type
Small molecule
Targets
p38 MAPK alpha/beta (MAPK14)
Mechanism
Inhibitor of p38 MAPK alpha/beta (MAPK14)
Pathways
p38 MAPK signaling, proinflammatory cytokine production
Therapy area
Infectious disease, Musculoskeletal
Developer
Fulcrum Therapeutics (FULC)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
F2DQF16BXE

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05397470 Phase 3 Facioscapulohumeral Muscular Dystrophy (FSHD) Terminated FULC
NCT04511819 Phase 3 COVID-19 Terminated FULC
NCT05002231 Phase 1 Healthy Adult Subjects Completed FULC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

COVID-19Facioscapulohumeral Muscular Dystrophy (FSHD)Healthy Adult Subjects

Other drugs acting on MAPK14

More from Fulcrum Therapeutics

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the FULC page.

Follow FULC, the company behind Losmapimod

See FULC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

FULC catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.